欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2006, Vol. 11 ›› Issue (6): 601-605.

• 综述 •    下一篇

二肽肽酶I研究进展

杨亚彬, 袁胜涛, 张陆勇   

  1. 中国药科大学江苏省新药筛选中心, 南京 210038, 江苏
  • 收稿日期:2006-04-11 修回日期:2006-05-15 出版日期:2006-06-26 发布日期:2020-12-04
  • 通讯作者: 张陆勇,男,教授,博士生导师,主要研究方向为新药筛选及药物安全性评价。Tel:025-85391036 E-mail:drugscreen@126.com
  • 作者简介:杨亚彬,男,硕士在读。Tel:13814007670 E-mail:atlanticer@hotmail.com
  • 基金资助:
    国家“十五” 重大专项(No2002AA2Z343E);国家“十五” 滚动项目(No2004AA2Z3785);江苏省药效研究和评价服务中心(NoBM2005103)

Overview and research progress of dipetidyl peptidase I

YANG Ya-bin, YUAN Sheng-tao, ZHANG Lu-yong   

  1. Jiangsu Center for drugscreening, China Pharmaceutical University, Nanjing 210038, Jiangsu, China
  • Received:2006-04-11 Revised:2006-05-15 Online:2006-06-26 Published:2020-12-04

摘要: 二肽肽酶I (dipeptidyl peptidase I, DPPI) 也叫组织蛋白酶C(cathepsin C), 是溶酶体内一种重要的内切蛋白酶。研究表明, DPPI 参与多种细胞(T 细胞、肥大细胞等) 颗粒内丝氨酸蛋白酶的翻译后处理和激活, 以及其他蛋白的降解过程, 从而在机体的细胞免疫、炎症反应等一系列病理生理过程中起到重要作用。人DPPI 基因的突变失活与三种罕见的遗传病(帕-勒氏综合征等) 密切相关。对DPPI 的选择性抑制有希望成为一种有效的治疗手段, 用于免疫调节、慢性炎症和细胞毒淋巴细胞瘤等疾病。

关键词: 二肽肽酶I, 组织蛋白酶C, 酶原激活, 帕-勒氏综合征, 酶抑制剂

Abstract: Dipeptidyl peptidase I (DPPI), a lysosomal cysteine proteinase also known as cathepsin C, functions as a key enzyme in the activation of many granule serine proteases in the granules of activated cytotoxic T lymphocytes and natural killer cells (granzymes A and B), mast cells (chymase and tryptase), and neutrophils (cathepsin G, proteinase 3 and elastase).It is well established that DPPI-deficient mice have severe defects in serine protease activities in these hemopoietic lineages.In light of the present investigators'work regarding the important role of DPPI-dependent effector on mechanisms in several human pathophysiological processes, the development of selective DPPI inhibitors would provide an important therapeutic tool in the treatment of immune inflammation lymphoma-related diseases.

Key words: dipeptidyl peptidase I, cathepsin C, proenzyme activation, Papillon-Lefevre syndrome, enzyme inhibitor

中图分类号: